Immunomedics, Inc. (IMMU)’s Stock Formed A Several Months Bullish Double Top Pattern

March 19, 2018 - By Louis Casey

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It is positive, as 16 investors sold Immunomedics, Inc. shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported.
Aqr Capital Mngmt Lc invested in 0% or 95,265 shares. Noven Gp Inc Inc has invested 0.12% in Immunomedics, Inc. (NASDAQ:IMMU). Renaissance Technologies Ltd Liability Corporation owns 1.44 million shares for 0.02% of their portfolio. Bankshares Of New York Mellon has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 681,419 shares. 1.95M were reported by Ghost Tree Cap Llc. Ra owns 1.48 million shares for 1.87% of their portfolio. Weiss Multi holds 0.05% or 100,000 shares in its portfolio. Hightower Limited Liability Com reported 51,815 shares. Pub Employees Retirement Association Of Colorado reported 0% stake. Pictet Asset Ltd stated it has 0.04% in Immunomedics, Inc. (NASDAQ:IMMU). Alliancebernstein L P has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Jennison Associate Ltd Llc holds 0.03% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 1.81M shares. Vanguard Grp Inc Inc reported 0% stake. State Of Wisconsin Investment Board reported 81,000 shares or 0% of all its holdings. Thrivent Fincl For Lutherans has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU).

Since February 28, 2018, it had 0 insider buys, and 1 insider sale for $2.05 million activity.

The chart of Immunomedics, Inc. (IMMU) shows a double top with $16.71 target or 7.00 % above today’s $15.62 share price. The 6 months chart pattern indicates low risk for the $2.59 billion company. It was reported on Mar, 19 by If the $16.71 price target is reached, the company will be worth $181.23M more. Double tops are rare but powerful chart patterns.

The stock decreased 2.13% or $0.34 during the last trading session, reaching $15.62. About 3.80M shares traded or 54.00% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since March 19, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on May, 9. They expect $-0.13 earnings per share, up 40.91 % or $0.09 from last year’s $-0.22 per share. After $-0.19 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -31.58 % EPS growth.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies downgraded the shares of IMMU in report on Wednesday, July 29 to “Hold” rating. The rating was maintained by Cowen & Co on Monday, July 24 with “Buy”. The rating was maintained by Jefferies with “Buy” on Wednesday, December 6. Jefferies maintained the shares of IMMU in report on Monday, October 9 with “Buy” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Friday, June 9. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Thursday, August 17 with “Buy” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Wednesday, December 6 by Cowen & Co. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) rating on Tuesday, September 19. Jefferies has “Buy” rating and $14.0 target. On Tuesday, March 15 the stock rating was maintained by Jefferies with “Hold”. The firm has “Buy” rating by Jefferies given on Friday, May 6.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.